New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 24, 2013
06:12 EDTATHXAthersys files to sell 10M shares of common stock for Aspire Capital Fund
Athersys will not receive proceeds from the sale of our shares by Aspire Capital. However, it may receive proceeds of up to $25M from the sale of our common stock to Aspire Capital pursuant to that purchase agreement it entered into with Aspire Capital.
News For ATHX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
12:21 EDTATHXOn The Fly: Top stock stories at midday
Subscribe for More Information
11:04 EDTATHXAthersys data provide 'glimmer of activity,' says Piper Jaffray
Subscribe for More Information
10:07 EDTATHXHigh option volume stocks
Subscribe for More Information
09:14 EDTATHXOn The Fly: Pre-market Movers
Subscribe for More Information
06:27 EDTATHXAthersys says MultiStem missed primary, secondary endpoints
Subscribe for More Information
05:56 EDTATHXStocks with implied volatility above IV index mean; ATHX GMCR
Stocks with implied volatility above IV index mean; Athersys (ATHX) 415, Keurig Green Mountain (GMCR) 52 according to iVolatility.
April 16, 2015
11:09 EDTATHXAthersys upcoming data could take shares to 45c, says Piper Jaffray
Subscribe for More Information
07:16 EDTATHXAthersys volatility elevated into Phase 2 ischemic stroke trial results
Athersys April call option implied volatility is at 408, May is at 390, July is at 230, October is at 204; compared to its 26-week average of 161 according to Track Data, suggesting large price movement into Phase 2 ischemic stroke trial results to be presented at ESOC.
05:59 EDTATHXStocks with implied volatility above IV index mean; ATHX GMCR
Stocks with implied volatility above IV index mean; Athersys (ATHX) 390, Keurig Green Mountain (GMCR) 53 according to iVolatility.
April 15, 2015
06:07 EDTATHXStocks with implied volatility above IV index mean; ATHX WETF
Subscribe for More Information
April 13, 2015
07:38 EDTATHXAthersys volatility elevated into Phase 2 ischemic stroke trial results
Subscribe for More Information
April 8, 2015
10:31 EDTATHXAthersys says Phase 2 ischemic stroke trial results to be presented at ESOC
Athersys announced that Dr. David Hess, a stroke specialist and Chairman of the Department of Neurology at the Medical College of Georgia Regents University, and the lead principal investigator in the study, will present the preliminary results from its Phase 2 clinical trial administering MultiStem for the treatment of ischemic stroke. The presentation will take place at the European Stroke Organization Conference 2015 on Sunday, April 19th starting at 8:50 am in Glasgow, Scotland, United Kingdom. Dr. Hess' presentation will be in the Boisdale Room of the Scottish Exhibition and Conference Centre in Glasgow, in the conference venue.Athersys' double-blind, placebo-controlled Phase 2 clinical trial is being conducted at leading stroke centers across the United States and in the United Kingdom to evaluate the safety and efficacy of its proprietary MultiStem cell therapy in adults who have suffered a severe ischemic stroke and are treated 24-48 hours following the stroke. Dr. Hess served as the lead clinician for the Phase 2 clinical trial, which also included clinical research teams from Oregon Health Sciences University, Houston Methodist Hospital, University of Pittsburgh Medical Center, Cleveland Clinic, Newcastle Upon Tyne and Stoke on Trent, among others. Trial enrollment was completed in December 2014 and this will be the first presentation of the unblinded results.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use